Cibus, Inc. is an agricultural technology company that uses gene editing technologies to develop plant traits in seeds. Its business is the development of plant traits that help address specific productivity or yield challenges in farming, such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate. It is also engaged in developing, certain alternative plant-based oils or bio-based fermentation products. Its technology is its gene editing platform called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits, four of which are applicable to multiple crops. These traits are PSR in Canola and HT1 and HT3 in rice. In addition, it also has two advanced traits for Sclerotinia resistance and another novel broadleaf HT trait, HT2.
BörsenkürzelCBUS
Name des UnternehmensCibus Inc
IPO-datumJul 20, 2017
CEODr. Peter Ronald Beetham, Ph.D.
Anzahl der mitarbeiter157
WertpapierartOrdinary Share
GeschäftsjahresendeJul 20
Addresse6455 Nancy Ridge Drive
StadtSAN DIEGO
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92121
Telefon18584500008
Websitehttps://www.cibus.com/
BörsenkürzelCBUS
IPO-datumJul 20, 2017
CEODr. Peter Ronald Beetham, Ph.D.
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten